Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015 Apr; 16(4):447-56.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Double-Blind Method
Drug-Related Side Effects and Adverse Reactions
Female
Humans
Hydroxamic Acids
Kaplan-Meier Estimate
Lung Neoplasms
Male
Mesothelioma
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Placebos

authors with profiles

Hedy Kindler